ARAT technique: After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
Study summary
The peroral endoscopic myotomy for the treatment of achalasia is associated with a higher incidence of gastroesophageal reflux disease compared with Heller's myotomy. Remodeling of the esophagogastric junction with hybrid argon plasma could decrease the passage of gastric or gastroduodenal content into the esophagus.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Achalasia type I, II, III
* Treatment with POEM (Peroral Endoscopic Myotomy)
* Abnormal acid exposure (\>6%) in the 24h-pHmetry test more than three months after the procedure
* Signed informed consent
Exclusion Criteria:
* Patients who do not accept the treatment
* Previous antireflux surgery
* Previous Heller's Myotomy
* Hiatal hernia greater than 3 centimeters
* Hill's Classification Grade IV
* Pregnancy
* Patients with any contraindication for an endoscopy
* Patients with esophageal or gastric varices
Primary outcome measure(s)
A change in erosive esophagitis grade assessed by upper endoscopy after ARAT — measures will be performed at 3,6 and 12 months after ARAT Upper endoscopy is going to be used to measure the erosive esophagitis grade using the Los Angeles Esophagitis scale(grade A=mild, Grade B=moderate, Grade C=moderate high and Grade D=severe) after after ARAT
A change in esophageal acid exposure assessed by pHmetry study after ARAT — measures will be performed at 3,6 and 12 months after ARAT A 24-hours pHmetry study is going to be used to measure esophageal acid exposure in esophagus after ARAT. DeMeester Score and the percentage of esophagic acid exposure will be used to assess pathologic reflux (\>14.73 and \> 6%, respectively)
A change in clinical symptoms of reflux disease assessed with a gastroesophageal reflux questionnaire after ARAT — measures will be performed at 3,6 and 12 months after ARAT The clinical evaluation of reflux disease is going to be assessed by the use of a clinical gastroesophageal reflux disease questionnaire (GERD-Q) after ARAT. Reflux disease was considered positive when \>4 points is observed
Trial sites (1)
Facility
City
Region
Status
Centro Medico Nacional Siglo XXI Hospital de Especialidades
Mexico City
Mexico City
More Coordinación de Investigación en Salud, Mexico trials in Mexico
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.